SCHEMBL2936083

SCHEMBL2936083

Cc1cc(C(=O)N2CCN(C)CC2)ccc1-c1cncc(-c2ccc(O)cc2)n1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 4/20 0.50
MKNK2 Q9HBH9 4/20 0.50
CHEK1 O14757 3/20 0.49
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C9 P11712 1/20 0.44
SRC P12931 3/20 0.44
PDGFRB P09619 1/20 0.44
POLB P06746 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
ABL1 P00519 1/20 0.43
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43
ATR Q13535 1/20 0.42
EGLN1 Q9GZT9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934546 0.88 MEN1 (0.53) MKNK1MKNK2CHEK1MEN1KMT2A
SCHEMBL13515277 0.83 FASN (0.50) MKNK1MKNK2CHEK1MEN1KMT2A
SCHEMBL2933923 0.83 KCNH2 (0.57) MKNK1MKNK2CHEK1ALDH1A1MAPT
SCHEMBL2932525 0.78 LRRK2 (0.46) MKNK1MKNK2CHEK1SRCPDGFRB
SCHEMBL13515300 0.78 MKNK1 (0.46) MKNK1MKNK2CHEK1KMT2ASRC
Trifluoroacetic Acid SCHEMBL2931457 0.78 FASN (0.46) MKNK1MKNK2CHEK1HPGDSRC
SCHEMBL2931418 0.78 SRC (0.49) MKNK1MKNK2KMT2ASRCALDH1A1
SCHEMBL2934437 0.77 TTK (0.52)
SCHEMBL13515311 0.77 PIM3 (0.54) MKNK1MKNK2CHEK1HPGDPOLB
SCHEMBL7882534 0.74 POLB (0.57) MKNK1MKNK2MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
CN-101472912-A Pyridine and pyrazine derivatives as MNK kinase inhibitors BIOVITRUM AB PUBL (SE) 2009-07-01 CN disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 MKNK1 75/4885MKNK2 39/4885CHEK1 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.